Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 82,800 shares, a decrease of 31.0% from the September 30th total of 120,000 shares. Based on an average daily volume of 62,300 shares, the short-interest ratio is currently 1.3 days. Currently, 3.7% of the company’s stock are short sold.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ALGS. Acadian Asset Management LLC raised its stake in shares of Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after purchasing an additional 171,490 shares in the last quarter. Opaleye Management Inc. raised its stake in shares of Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Trading Down 7.0 %

ALGS stock traded down $0.63 during trading on Friday, reaching $8.40. The stock had a trading volume of 201,203 shares, compared to its average volume of 35,139. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00. The company has a market capitalization of $656.12 million, a P/E ratio of -6.56 and a beta of 2.16. The firm has a fifty day moving average price of $10.59 and a 200 day moving average price of $13.44.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million for the quarter. During the same quarter in the prior year, the firm earned ($10.75) EPS. Sell-side analysts predict that Aligos Therapeutics will post -8.2 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Wednesday.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).